This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer.

Coverage of stories discussed this week on ascopost.com:

Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma

AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer